FDA Urged To Emphasize Post-Market Safety Monitoring Over Pre-Approval Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s drug approval system places too much emphasis on pre-approval testing and not enough on post-marketing surveillance, Stanford University Center for Health Policy Director Garber suggests. Vioxx is the most recent example of safety problems not evident until after widespread use, he says.